Maria T. Pallotta
Perugia, 06132, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Discovery of a Dual IDO1/TDO Inhibitor That Modulates Enzymatic Activity and IDO1/SHP-2 Signaling.
Journal: Journal of medicinal chemistry
Published: July 22, 2026
Adverse pro-tumorigenic effects of IDO1 catalytic inhibitors mediated by the non-enzymatic function of IDO1 in tumor cells.
Journal: Frontiers in immunology
Published: August 06, 2025
Gallic acid released by a layered double hydroxide-coated scaffold of hydroxyapatite and β-tricalcium phosphate inhibits the osteoclast formation In Vitro.
Journal: Biomaterials and biosystems
Published: May 27, 2025
Identification of a Compound Inhibiting Both the Enzymatic and Nonenzymatic Functions of Indoleamine 2,3-Dioxygenase 1.
Journal: ACS pharmacology & translational science
Published: May 03, 2024
Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Journal: Frontiers in immunology
Published: November 29, 2023
Membrane Localization and Phosphorylation of Indoleamine 2,3-Dioxygenase 2 (IDO2) in A549 Human Lung Adenocarcinoma Cells: First Steps in Exploring Its Signaling Function.
Journal: International journal of molecular sciences
Published: September 18, 2023
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder.
Journal: Frontiers in clinical diabetes and healthcare
Published: February 21, 2023
The signaling function of IDO1 incites the malignant progression of mouse B16 melanoma.
Journal: Oncoimmunology
Published: February 03, 2023
The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1.
Journal: Frontiers in immunology
Published: December 30, 2022
Unconventional Pathways of Protein Secretion: Mammals vs. Plants.
Journal: Frontiers in cell and developmental biology
Published: March 14, 2022
Last Updated: 09/26/2026